Kissei Pharmaceutical Co., Ltd.
KSPHF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $160 | $22,191 | $22,661 | $23,203 |
| % Growth | -99.3% | -2.1% | -2.3% | – |
| Cost of Goods Sold | $81 | $11,111 | $11,714 | $11,483 |
| Gross Profit | $78 | $11,080 | $10,947 | $11,720 |
| % Margin | 49.1% | 49.9% | 48.3% | 50.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $139 | $8,971 | $9,411 | $9,264 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1 | $1 | -$1 |
| Operating Expenses | $139 | $8,972 | $9,412 | $9,263 |
| Operating Income | -$60 | $2,108 | $1,535 | $2,457 |
| % Margin | -37.8% | 9.5% | 6.8% | 10.6% |
| Other Income/Exp. Net | $85 | $3,639 | $2,502 | $1,957 |
| Pre-Tax Income | $25 | $5,747 | $4,037 | $4,414 |
| Tax Expense | $2 | $1,227 | $916 | $811 |
| Net Income | $22 | $4,519 | $3,121 | $3,591 |
| % Margin | 13.8% | 20.4% | 13.8% | 15.5% |
| EPS | 0.53 | 107.87 | 72.91 | 82.99 |
| % Growth | -99.5% | 47.9% | -12.1% | – |
| EPS Diluted | 0.53 | 107.87 | 72.91 | 82.99 |
| Weighted Avg Shares Out | 41 | 42 | 43 | 43 |
| Weighted Avg Shares Out Dil | 41 | 42 | 43 | 43 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $686 | $115 | $587 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $8 | $1,154 | $1,154 | $1,064 |
| EBITDA | $33 | $3,263 | $2,690 | $3,520 |
| % Margin | 20.5% | 14.7% | 11.9% | 15.2% |